You are here

Automated Ultra-Long DNA and RNA Extraction for Long-read Sequencing Applications

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44GM131530-02A1
Agency Tracking Number: R44GM131530
Amount: $2,032,292.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: 400
Solicitation Number: PA19-272
Timeline
Solicitation Year: 2019
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-05-01
Award End Date (Contract End Date): 2023-04-30
Small Business Information
1182 MONTE VISTA AVE #11
Upland, CA 91786-8205
United States
DUNS: 781016386
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MARK BROWN
 (909) 706-2975
 mbrown@claremontbio.com
Business Contact
 TRACY DOEBLER
Phone: (909) 920-5789
Email: tdoebler@claremontbio.com
Research Institution
N/A
Abstract

Summary
Claremont BioSolutions, LLC (CBIO)
The ability to sequence and map long stretches of DNA and RNA using third generation sequencing
technologies is set to transform the field of genomics and allow researchers and clinicians unparalleled insight
into the complexities of our genome and diseases. However, the move to these platforms presents new
hurdles in long DNA and RNA sample preparation. Most conventional spin column sample preparation
methods shear DNA during purification, and although agarose plug digestion methods can isolate ultra-long
DNA from samples, the protocols can be difficult, time consuming and highly variable. While newer
technologies have emerged that allow for more rapid extraction of long-DNA, these kits are either limited in use
to easy-to-lyse sample types (cells and blood) or require extra equipment and long processing times, which
significantly increases the cost. At Claremont BioSolutions (CBio), we are developing a novel automated
extraction technology that will incorporate lysis, nucleic acid binding and isolation. The technology will allow
users to add and sample, hit “GO” and in 30 minutes collect DNA or RNA. In Aim 1, we will integrate our fast
lysis and isolation technology into an automated cartridge to provide reproducible high quality, ultra-long DNA
or RNA extraction. In Aim 2, we will validate automated ultra-long DNA extraction using easy and complex
sample types, compare our technology to HMW DNA competitor's kits, and demonstrate improved long-read
sequencing using two third generation technologies. In Aim 3 we will test automated RNA extraction and
downstream native RNA sequencing. In Aim 4 we will perform pre-market analysis at off-site alpha and beta
testing facilities to generate end-user feedback and lockdown the design. The proposed system would simplify
workflow, lower cost, and reduce variability.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government